MedTrace Logo

The Utility of Breath Biopsy as a Screening Tool for HCC

NCT04326491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2022-05-20

No results posted yet for this study

Summary

The aim of this pilot study is to examine whether there is a discriminating ability of the breath sample analysis to capture biomarkers specific to the HCC in the breath of affected individuals. If positive, our research could open up a new horizon for cost-effective and feasible screening tools.

Conditions

  • HCC
  • Cirrhosis, Liver

Interventions

DIAGNOSTIC_TEST

Breath Biopsy

Analysis of breath samples to identify volatile molecules specific to HCC

Sponsors & Collaborators

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Mohamed Bekheit, PhD · NHS Grampian

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-20
Primary Completion
2022-05-16
Completion
2022-05-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04326491 on ClinicalTrials.gov